Skip to main content

Table 1 Subgroups dependent on type of treatment

From: The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study

A First-line treatment

A1 Patients unsuitable for

 

 (n = 36, 51.4%)

 SCT/high-dose chemotherapy (n = 6, 8.6%)

 
 

 all obtained novel agent based therapy

 
 

A2 Patients qualifying for

A2a High-dose chemotherapy with

 

 transplant based concept (n=30, 42.8%)

 autologous SCT (n = 9, 12.9%)

  

A2b High-dose chemotherapy with

  

 tandem-SCT (n = 21, 30.0%)

  

 auto/auto (n = 18, 25.7%)

  

 auto/allo (n = 3, 4.3%)

  

A2c High-dose chemotherapy with

  

 allogeneic SCT (n = 0)

B Higher treatment line

B1 Patients unsuitable for

 

 (n = 34, 48.6%)

 SCT/high-dose chemotherapy (n = 18, 25.7%),

 
 

 all obtained novel agent based therapy

 
 

B2 Patients qualifying for

B2a High-dose chemotherapy with

 

 transplant based concept (n = 16, 22.9%)

 autologous SCT (n = 8, 11.4%)

  

B2b High-dose chemotherapy with

  

 tandem-SCT (n = 4, 5.7%)

  

 auto/auto (n = 3, 4.3%)

  

 auto/allo (n = 1, 1.4%)

  

B2c High-dose chemotherapy with

  

 allogeneic SCT (n = 4, 5.7%)